Hormone Receptor-Positive Advanced Breast Cancer : Challenges and New Treatment Options
WebcastFaculty
OVERVIEW
Hormone Receptor-Positive Advanced Breast Cancer : Challenges and New Treatment Options is organized by Cleveland Clinic Center for Continuing Education and would be held during Aug 23, 2017 - Aug 23, 2018.
The target audience for this medical event for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer. This CME Conference has been approved with a maximum of 1.25 AMA PRA Category 1 Credits.
Description :
This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B-42, breast cancer index and other biomarkers.
Learning Objectives :
• Identify the current standard of care for endocrine therapy in patients with hormone receptor-positive advanced breast cancer
• Discuss key results of clinical trials of fulvestrant, alone and in combination regimens, for treatment of HR-positive disease
• State the mechanism of action of CDK4/6 inhibitors and rationale for their use in HR-positive advanced breast cancer
• Assess the efficacy and safety of CDK4/6 inhibitors observed in recent clinical trials in women with HR-positive, HER2-negative breast cancer and its potential to overcome endocrine resistance
• Explain the rationale for use of mTOR inhibitors for treatment of patients with HR-positive advanced breast cancer, and summarize recent clinical trial data supporting the efficacy of such agents in this patient population
• Review biomarker driven decision making in adjuvant and extended adjuvant setting
Additional details will be posted as soon as they are available.
The target audience for this medical event for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer. This CME Conference has been approved with a maximum of 1.25 AMA PRA Category 1 Credits.
Description :
This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B-42, breast cancer index and other biomarkers.
Learning Objectives :
• Identify the current standard of care for endocrine therapy in patients with hormone receptor-positive advanced breast cancer
• Discuss key results of clinical trials of fulvestrant, alone and in combination regimens, for treatment of HR-positive disease
• State the mechanism of action of CDK4/6 inhibitors and rationale for their use in HR-positive advanced breast cancer
• Assess the efficacy and safety of CDK4/6 inhibitors observed in recent clinical trials in women with HR-positive, HER2-negative breast cancer and its potential to overcome endocrine resistance
• Explain the rationale for use of mTOR inhibitors for treatment of patients with HR-positive advanced breast cancer, and summarize recent clinical trial data supporting the efficacy of such agents in this patient population
• Review biomarker driven decision making in adjuvant and extended adjuvant setting
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links